Dec. 22, 2023
By Mari Serebrov
OIG: US NIH audit oversight puts federal funds at risk
If two recent reports about the NIH’s oversight of its grant programs were grades, the U.S. agency would have received failing marks – again.
Dec. 20, 2023
Replay and Syena license NIH library of TCRs targeting cancer neoantigens
Replay Holdings LLC has entered into an exclusive, worldwide license agreement with the National Institutes of Health (NIH) for intellectual property related to a library of T-cell receptors (TCRs) directed against multiple cancer neoantigens.
Dec. 14, 2023
Delix awarded NIDA grant to support development of neuroplastogen for substance use disorders
Delix Therapeutics Inc. has been awarded a $320,000 grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to support the advancement of DLX-007.

Authors